Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!

Pat is one of three finalists for this year’s award, alongside two friends and compatriots in the fight against cancer: Asem Mansour of King Hussein Cancer Center in Jordan, and Wondu Bekele Woldemariam of Mathiwos Wondu-YeEthiopia Cancer Society. Our thanks and congratulations go out to all three finalists for their tremendous impact and visionary leadership. The world is a better place for their contributions.

We would also like to thank the 18 different Patient Associations from around the world that sent letters in support of Pat’s nomination. You are the inspiration for all we do and we are so very grateful for your support.

The winner of the award will be announced on October 2nd at this year’s World Cancer Congress in Kuala Lumpur. Representatives from The Max Foundation and patient advocates from across Asia will be in attendance to share their knowledge, their experiences, and, of course, to cheer on Pat!

Visit the UICC website to learn more about the awards and the finalists.

 

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.

  • Welcoming Two New Board Members: Dr. Mika Matsuzaki and Dr. Susan M. Jerian

    Please join us in welcoming Mika Matsuzaki, PhD, and Susan M. Jerian, MD to The Max Foundation Board of Directors.

  • Acting with humanity – donating my birthday – supporting cancer patients in Nepal

    Acting with humanity – donating my birthday – supporting cancer patients in Nepal

    Watch webinar on “Overcoming Barriers to Pediatric Cancer Care in Nepal” Last October I had the privilege of visiting Patan Hospital in Nepal on behalf of The Max Foundation. Right then, I knew I would dedicate my next birthday to supporting people in need of cancer treatment in the country by covering the cost of diagnostics….